Showing 1291-1300 of 1614 results for "".
- Nordic Pharma’s Lacrifill Canalicular Gel Highlighted in DEWS III Reporthttps://modernod.com/news/nordic-pharmas-lacrifill-canalicular-gel-highlighted-in-landmark-dews-iii-report/2482927/Nordic Pharma, a subsidiary of Nordic Group BV, announced that its Lacrifill Canalicular Gel—a novel therapy for the relief of dry eye symptoms—has been featured in the newly released Dry Eye Workshop (DEWS) III report from the Tear Film and O
- Johnson & Johnson Appoints Kelly Heaps, Vice President of US Sales, Vision Carehttps://modernod.com/news/johnson-johnson-appoints-kelly-heaps-vice-president-of-us-sales-vision-care/2482879/Johnson & Johnson announced the appointment of Kelly Heaps as Vice President of US Sales, Vision Care. As the leader of the US Sales Organization, Ms. Heaps will work to accelerate sales and foster market share growth while collaborating with customers to strengthen patient outcomes.
- Formycon and Bio Usawa Partner Bio to Provide FYB201/ BioUcenta (Ranibizumab) Across Sub-Saharan Africahttps://modernod.com/news/formycon-and-bio-usawa-partner-bio-to-provide-fyb201-bioucenta-ranibizumab-across-sub-saharan-africa/2482870/Formycon announced a partnership between Bioeq AG—licensee and exclusive global commercialization rights holder for Formycon’s biosimilar FYB201—and African biotechnology company Bio Usawa Biotechnology. The agreement grants Bio Usawa exclusiv
- Sydnexis Announces European Commission Approval of Ryjunea, the First Treatment for Slowing the Progression of Pediatric Myopiahttps://modernod.com/news/sydnexis-announces-european-commission-approval-of-ryjunea-first-treatment-for-slowing-the-progression-of-pediatric-myopia/2482839/The European Commission (EC) has granted marketing authorization for Sydnexis' SYD-101 (branded as Ryjunea), the company’s proprietary low-dose atropine formulation, for slowing the progression of pediatric myopia.
- EssilorLuxottica to Acquire European Ophthalmology Network Optegra Clinicshttps://modernod.com/news/essilorluxottica-to-acquire-ophthalmology-network-optegra-clinics/2482825/EssilorLuxottica and MidEuropa have entered into an agreement in which EssilorLuxottica will acquire Optegra, an integrated ophthalmology platform operating in five European markets: the UK, Czech Republic, Poland, Slovakia and the Netherlands. Financial terms of the deal were
- Ocular Therapeutix To Close Enrollment this Week for SOL-R Trial Evaluating Axpaxli in Wet AMDhttps://modernod.com/news/ocular-therapeutix-to-close-enrollment-this-week-for-sol-r-trial-evaluating-axpaxli-in-wet-amd/2482822/Ocular Therapeutix announced that enrollment in the SOL-R registrational trial of its product candidate Axpaxli in wet age-related macular degeneration (AMD) will close this week. “Completing enrollment in SOL-R—the largest retinal TKI trial to date—one year
- Ace Vision Group Closes $29.4 Million Series B Financing Roundhttps://modernod.com/news/ace-vision-group-closes-294-million-series-b-financing-round/2482767/Ace Vision Group announced the successful close of a $29.4 million Series B financing round. The new capital will support the continued development of the company’s proprietary Gen II VisioLite Ophthalmic Laser, which delivers the minimally invasive LSM procedure—a treatment targ
- Allotex Accelerates into Commercial Phase and Appoints Michael Mrochen as New CEOhttps://modernod.com/news/allotex-accelerates-into-commercial-phase-and-appoints-michael-mrochen-as-new-ceo/2482755/Allotex, which has developed the first natural, human collagen-based eye implant designed to help people over 40 restore their near vision, announced progress in its commercial rollout across global markets. Following market clearance in Europe, Canada, South Africa, Türkiye, and A
- First Atropine Eye Drop to Slow Myopia Progression in Children Approved in Indiahttps://modernod.com/news/first-atropine-eye-drop-to-slow-myopia-progression-in-children-approved-in-india/2482750/Entod Pharmaceuticals announced it has received marketing authorisation from the Central Drugs Standard Control Organisation (CDSCO) for the first 0.05% atropine eye drops (Myatro XL) developed to slow the progression of myopia in children age 6 to 12. This milestone foll
- Andrew Chang Joins BVI Medical as Chief Commercial Officerhttps://modernod.com/news/andrew-chang-joins-bvi-medical-as-chief-commercial-officer/2482735/BVI Medical announced the appointment of Andrew Chang to the newly created role of Chief Commercial Officer. Mr. Chang will lead the company’s global sales, global marketing, and commercial excellence teams and will report directly to President and CEO Shervin Korangy. Mr. Ch